DZL scientists at the Hospital for Thoracic Diseases at Heidelberg University Hospital (UKHD) and the National Center for Tumor Diseases (NCT) Heidelberg have been working with an interdisciplinary team to establish an individual treatment of a rare form of lung cancer. The basis for this is identifying a molecular risk factor and deciphering the role of the immunological tumor microenvironment.

The researchers have gained important insights with genetic and transcriptomic analyses, coupled with clinical knowledge. They succeeded in identifying concurrent TP53 mutations as a new molecular risk factor and in unraveling the role of the immunological tumor microenvironment for patient survival.

Article:

Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, Thomas. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. European Journal of Cancer. In press; doi: 10.1016/j.ejca.2022.04.020.

Source (only in German): Individuelle Behandlung von seltenem Lungenkrebs: neue Erkenntnisse zu molekularem Risikofaktor und Tumormikroumgebung - NCT Nationales Centrum für Tumorerkrankungen Heidelberg (nct-heidelberg.de)